1. Dapagliflozin Decreases Plasma Lipoprotein(A) in High CV Risk Patient In Type 2 Diabetes Patient with Underlying Ischaemic Heart Disease. (15th December 2018) Authors: Nur Aisyah, Z.; Rohana, A.G.; Faradilla, W.H.S.; Fatimah, Z.M.S.; Huda, ; Zaliha, ; Nur Atikah, D. Journal: International journal of cardiology Issue: Volume 273(2018)Supplement Page Start: 12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Dapagliflozin Preserves Vascular Endothelial Function and Improves Glycemic Control in High CV Risk Patients with Type 2 Diabetes Mellitus: Edified Study. (15th December 2018) Authors: Nur Aisyah, Z.; Rohana, A.G.; Faradilla, W.H.S.; Fatimah, Z.M.S.; Huda, ; Zaliha, ; Nur Atikah, D. Journal: International journal of cardiology Issue: Volume 273(2018)Supplement Page Start: 12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗